Miguel Abboud to Antineoplastic Agents
This is a "connection" page, showing publications Miguel Abboud has written about Antineoplastic Agents.
Connection Strength
0.499
-
Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon. Int J Hematol. 2012 Oct; 96(4):521-4.
Score: 0.238
-
Hematopoietic stem-cell transplantation for adults with sickle cell disease. N Engl J Med. 2009 Dec 10; 361(24):2380-1.
Score: 0.196
-
Abdominal complications of chemotherapy in pediatric malignancies: imaging findings. Clin Imaging. 2009 Jul-Aug; 33(4):253-60.
Score: 0.048
-
L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. Neuropediatrics. 2008 Feb; 39(1):46-50.
Score: 0.011
-
Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):242-6.
Score: 0.006